iShares Core MSCI China Index ETF(02801.HK) Rose 0.40% to 25.120
Newtimespace News, as of 13:13 on May 19, iShares Core MSCI China Index ETF(02801.HK) was quoted at HKD 25.120, up 0.40%. The ETF opened at HKD 25.000, with a high of HKD 25.260 and a low of HKD 25.000. The latest Net Asset Value (NAV) per unit is HKD 25.078, with a premium rate of -0.23%. The asset size is approximately HKD 15.581 billion.
iShares Core MSCI China Index ETF(02801.HK) tracks the MSCI China Index, which is compiled and published by the global leading index provider MSCI Inc. The index aims to comprehensively reflect the overall performance of Chinese listed companies. Its constituent stocks have broad coverage, including A-shares and B-shares listed on the Shanghai and Shenzhen Stock Exchanges, H-shares, Red Chips, and private enterprise shares listed on The Stock Exchange of Hong Kong, as well as Chinese companies listed overseas. The index is constructed according to the MSCI Global Investable Market Indexes methodology, investing in highly liquid Chinese listed companies. It covers multiple core sectors such as Financials, Energy, Telecommunication Services, Information Technology, Industrials, Consumer Staples, Consumer Discretionary, Materials, Utilities, and Health Care.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment